Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant chemotherapy: results and perspectives

W K Evans1

  • 1Ottawa Regional Cancer Centre, Ontario, Canada.

Lung Cancer (Amsterdam, Netherlands)
|April 1, 1995
PubMed
Summary

Adjuvant chemotherapy for non-small cell lung cancer (NSCLC) shows modest survival benefits in some studies. More effective systemic therapies are needed for improved outcomes in NSCLC patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review.

ESMO open·2022
Same author

Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada.

Current oncology (Toronto, Ont.)·2020
Same author

Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada.

Current oncology (Toronto, Ont.)·2020
Same author

Smoking Cessation in Cancer Care: Myths, Presumptions and Implications for Practice.

Clinical oncology (Royal College of Radiologists (Great Britain))·2020
Same author

The generation of two specific cancer costing algorithms using Ontario administrative databases.

Current oncology (Toronto, Ont.)·2019
Same author

Cost-of-illness study for non-small-cell lung cancer using real-world data.

Current oncology (Toronto, Ont.)·2019

Area of Science:

  • Oncology
  • Medical Oncology
  • Thoracic Surgery

Background:

  • The 5-year survival for surgically treated non-small cell lung cancer (NSCLC) is below 50%, highlighting the need for effective adjuvant therapies.
  • Existing adjuvant chemotherapy regimens, such as CAP, have shown mixed results in improving disease-free and overall survival.

Purpose of the Study:

  • To evaluate the efficacy of adjuvant chemotherapy in improving survival outcomes for non-small cell lung cancer patients.
  • To identify the need for more effective systemic adjuvant therapies in NSCLC treatment.

Main Methods:

  • Review of two Lung Cancer Study Group (LCSG) trials evaluating adjuvant CAP chemotherapy.
  • Analysis of a Finnish study randomizing patients with T1-T3, N0 disease to CAP chemotherapy or follow-up.
  • Examination of other adjuvant trials using vindesine and cisplatin.

Main Results:

  • Modest improvements in disease-free and overall survival were observed with adjuvant CAP in some LCSG studies.
  • A Finnish study demonstrated improved recurrence-free and overall survival at 5 and 10 years with CAP chemotherapy.
  • Some adjuvant trials, including an LCSG trial for Stage I NSCLC and studies with vindesine/cisplatin, showed no significant benefit.

Conclusions:

  • Current adjuvant chemotherapy regimens offer limited benefit for non-small cell lung cancer, necessitating the development of more effective systemic therapies.
  • Future research should focus on identifying high-risk patient subsets using biological markers for targeted adjuvant treatment strategies.
  • Randomized trials with careful intra-operative staging are crucial for evaluating novel adjuvant approaches in NSCLC.

Related Experiment Videos